Seladelpar cholestasis benefits extend long term

Dr Marlyn Mayo and Dr Andreas Kremer share key insights on primary sclerosing cholangitis from AASLD The Liver Meeting 2025, and explore the latest in therapeutic developments and symptomatology.

Dr Silvia Vilarinho and Dr Deepak Joshi share the highlights from AASLD The Liver Meeting 2025, with an emphasis on late-onset genetic cholestasis, and offer quick insights into new data on the growing utility of genetic testing and expanding therapeutic implications.

Dr Andreas Kremer and Dr Marlyn Mayo highlight key advances in primary biliary cholangitis from AASLD The Liver Meeting 2025, and provide quick insights into the latest data on next-generation therapies.

Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.

Marlyn Mayo discusses findings on physician attitudes to managing pruritus in PSC.

Giving seladelpar beyond 12 months offers primary biliary cholangitis patients improvements in pruritus and biochemical markers, show ongoing analyses.

A real-world analysis of PSC patients given maralixibat suggests it offers meaningful improvements in pruritus.

Most cases of unexplained cholestasis in adults have an identifiable underlying genetic cause.

Adults living with unexplained cholestasis could receive a diagnosis with next generation sequencing, suggests US study.

Marios Nikolaidis shares findings on the gut microbiome in PSC management.